Application 211730
- Type
- ANDA
- Sponsor
- APOTEX
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | FULVESTRANT | FULVESTRANT | INJECTABLE;INTRAMUSCULAR | 50MG/ML | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A211730-001 | FULVESTRANT | FULVESTRANT | 250MG/5ML (50MG/ML) | SOLUTION / INTRAMUSCULAR | 2021-06-11 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A211730-001 | FULVESTRANT | 250MG/5ML (50MG/ML) | SOLUTION / INTRAMUSCULAR | 2021-06-11 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A211730-001 | FULVESTRANT | 250MG/5ML (50MG/ML) | SOLUTION / INTRAMUSCULAR | 2021-06-11 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A211730-001 | FULVESTRANT | 250MG/5ML (50MG/ML) | SOLUTION / INTRAMUSCULAR | 2021-06-11 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A211730-001 | FULVESTRANT | 250MG/5ML (50MG/ML) | SOLUTION / INTRAMUSCULAR | 2021-06-11 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A211730-001 | FULVESTRANT | 250MG/5ML (50MG/ML) | SOLUTION / INTRAMUSCULAR | 2021-06-11 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A211730-001 | FULVESTRANT | 250MG/5ML (50MG/ML) | SOLUTION / INTRAMUSCULAR | 2021-06-11 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A211730-001 | FULVESTRANT | 250MG/5ML (50MG/ML) | SOLUTION / INTRAMUSCULAR | 2021-06-11 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A211730-001 | FULVESTRANT | 250MG/5ML (50MG/ML) | SOLUTION / INTRAMUSCULAR | 2021-06-11 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A211730-001 | FULVESTRANT | 250MG/5ML (50MG/ML) | SOLUTION / INTRAMUSCULAR | 2021-06-11 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A211730-001 | FULVESTRANT | 250MG/5ML (50MG/ML) | SOLUTION / INTRAMUSCULAR | 2021-06-11 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A211730-001 | FULVESTRANT | 250MG/5ML (50MG/ML) | SOLUTION / INTRAMUSCULAR | 2021-06-11 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A211730-001 | FULVESTRANT | 250MG/5ML (50MG/ML) | SOLUTION / INTRAMUSCULAR | 2021-06-11 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A211730-001 | FULVESTRANT | 250MG/5ML (50MG/ML) | SOLUTION / INTRAMUSCULAR | 2021-06-11 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A211730-001 | FULVESTRANT | 250MG/5ML (50MG/ML) | SOLUTION / INTRAMUSCULAR | 2021-06-11 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A211730-001 | FULVESTRANT | 250MG/5ML (50MG/ML) | SOLUTION / INTRAMUSCULAR | 2021-06-11 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | A211730-001 | FULVESTRANT | 250MG/5ML (50MG/ML) | SOLUTION / INTRAMUSCULAR | 2021-06-11 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A211730-001 | FULVESTRANT | 50MG/ML | INJECTABLE / INTRAMUSCULAR | 2021-06-11 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | A211730-001 | FULVESTRANT | 50MG/ML | INJECTABLE / INTRAMUSCULAR | 2021-06-11 | 5d02ea3f76ae… | ||
| 2022-04-04 05:41 UTC | 2022-04 | A211730-001 | FULVESTRANT | 50MG/ML | INJECTABLE / INTRAMUSCULAR | 2021-06-11 | 4b0b4de00fa7… | ||
| 2022-03-09 01:35 UTC | 2022-03 | A211730-001 | FULVESTRANT | 50MG/ML | INJECTABLE / INTRAMUSCULAR | 2021-06-11 | bb7c543d1eb4… | ||
| 2021-12-28 21:50 UTC | 2021-12 | A211730-001 | FULVESTRANT | 50MG/ML | INJECTABLE / INTRAMUSCULAR | AO | 2021-06-11 | 782e0a99824c… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A211730-001 | FULVESTRANT | 250MG/5ML (50MG/ML) | SOLUTION / INTRAMUSCULAR | 2021-06-11 | 6a51e52b5d6a… | ||
| 2024-02-18 07:12 UTC | 2024-02 | A211730-001 | FULVESTRANT | 250MG/5ML (50MG/ML) | SOLUTION / INTRAMUSCULAR | 2021-06-11 | 1c564ffb4f44… | ||
| 2023-12-20 04:57 UTC | 2023-12 | A211730-001 | FULVESTRANT | 250MG/5ML (50MG/ML) | SOLUTION / INTRAMUSCULAR | 2021-06-11 | ea1830bbd6c7… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A211730-001 | FULVESTRANT | 250MG/5ML (50MG/ML) | SOLUTION / INTRAMUSCULAR | 2021-06-11 | a72a2bbeb626… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A211730-001 | FULVESTRANT | 250MG/5ML (50MG/ML) | SOLUTION / INTRAMUSCULAR | 2021-06-11 | 9b2671bbb829… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A211730-001 | FULVESTRANT | 250MG/5ML (50MG/ML) | SOLUTION / INTRAMUSCULAR | 2021-06-11 | a67488948f0b… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A211730-001 | FULVESTRANT | 250MG/5ML (50MG/ML) | SOLUTION / INTRAMUSCULAR | 2021-06-11 | 3f0d92c62455… | ||
| 2023-05-13 08:27 UTC | 2023-05 | A211730-001 | FULVESTRANT | 250MG/5ML (50MG/ML) | SOLUTION / INTRAMUSCULAR | 2021-06-11 | 053a50430f4f… | ||
| 2023-01-26 05:58 UTC | 2023-01 | A211730-001 | FULVESTRANT | 250MG/5ML (50MG/ML) | SOLUTION / INTRAMUSCULAR | 2021-06-11 | 3bdfa0b2c4d7… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A211730-001 | FULVESTRANT | 250MG/5ML (50MG/ML) | SOLUTION / INTRAMUSCULAR | 2021-06-11 | 3a93d1ddd44b… | ||
| 2022-10-28 04:53 UTC | 2022-10 | A211730-001 | FULVESTRANT | 50MG/ML | INJECTABLE / INTRAMUSCULAR | 2021-06-11 | f41ea6bd6efb… | ||
| 2022-09-29 23:25 UTC | 2022-09 | A211730-001 | FULVESTRANT | 50MG/ML | INJECTABLE / INTRAMUSCULAR | 2021-06-11 | e64feba35796… | ||
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | A211730-001 | FULVESTRANT | 50MG/ML | INJECTABLE / INTRAMUSCULAR | 2021-06-11 | cb3db0bc1861… | ||
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211730-001 | FULVESTRANT | 250MG/5ML (50MG/ML) | SOLUTION / INTRAMUSCULAR | 2021-06-11 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2021-12-28 21:50 UTC | 2021-12 | A211730-001 | AO | 1 | 782e0a99824c… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| CLIGAVYX | FULVESTRANT | Avyxa Pharma, LLC | e20d8ca3-8837-4003-8b01-1ebec342062a | 2026-06-24 | Warnings, Adverse reactions | FULVESTRANT |
| fulvestrant | FULVESTRANT | Sagent Pharmaceuticals | d5ae9e07-73b0-4063-a9e4-0ffc5614c2b8 | 2026-03-05 | Warnings, Adverse reactions | fulvestrant FULVESTRANT |
| Fulvestrant | FULVESTRANT | GLENMARK PHARMACEUTICALS INC., USA | 99cf8b69-4c23-4886-80e9-b23e348b5bd7 | 2026-02-27 | Warnings, Adverse reactions | Fulvestrant FULVESTRANT |
| Fulvestrant | FULVESTRANT | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 46086fe7-190d-4963-97bc-1fe22d36e6d2 | 2025-12-23 | Warnings, Adverse reactions | Fulvestrant FULVESTRANT |
| Fulvestrant | FULVESTRANT | Alembic Pharmaceuticals Inc. | b02915fe-6c44-48c1-aaeb-997ddc59a595 | 2025-08-18 | Warnings, Adverse reactions | Fulvestrant FULVESTRANT |
| Fulvestrant | FULVESTRANT | BluePoint Laboratories. | 57352662-d2fa-4dce-828f-4c51e46e0b4d | 2025-07-25 | Warnings, Adverse reactions | Fulvestrant FULVESTRANT |
| Fulvestrant | FULVESTRANT | Eugia US LLC | 80b6dfe6-449d-4e2f-af90-bfbf9b04163b | 2025-07-03 | Warnings, Adverse reactions | Fulvestrant FULVESTRANT |
| Fulvestrant | FULVESTRANT | BluePoint Laboratories | bc7b4eac-3b63-53d2-e053-2995a90ad5e7 | 2025-06-24 | Warnings, Adverse reactions | Fulvestrant FULVESTRANT |
| Fulvestrant | FULVESTRANT | Amneal Pharmaceuticals LLC | f36f19ad-f044-4dba-80b6-d074ddffcd86 | 2025-05-30 | Warnings, Adverse reactions | Fulvestrant FULVESTRANT |
| Fulvestrant | FULVESTRANT | Amneal Pharmaceuticals LLC | a51aa693-b433-4b2d-a71b-9ba029b10ce3 | 2025-04-30 | Warnings, Adverse reactions | Fulvestrant FULVESTRANT |
| FULVESTRANT | FULVESTRANT | Accord Healthcare Inc. | b471eb51-488e-5312-e053-2a95a90a8116 | 2025-03-10 | Warnings, Adverse reactions | FULVESTRANT FULVESTRANT |
| Fulvestrant | FULVESTRANT | Hikma Pharmaceuticals USA Inc. | 306c283b-9abe-4985-856b-1957f1f3af8b | 2025-02-10 | Warnings, Adverse reactions | Fulvestrant FULVESTRANT |
| Fulvestrant | FULVESTRANT | Athenex Pharmaceutical Division, LLC. | 8ed06e0e-c17b-4c71-8d03-888bcde4a638 | 2025-01-28 | Warnings, Adverse reactions | Fulvestrant FULVESTRANT |
| FULVESTRANT | FULVESTRANT | Zydus Pharmaceuticals USA Inc. | 994edf79-20a5-4e3a-bb35-c4fe3e65acba | 2024-08-20 | Warnings, Adverse reactions | FULVESTRANT FULVESTRANT |
| Fulvestrant | FULVESTRANT | Dr.Reddy's Laboratories Inc | 2fc17ba3-83c7-a2b4-8a75-6a0cb1e07682 | 2024-07-31 | Warnings, Adverse reactions | Fulvestrant FULVESTRANT |
| Fulvestrant | FULVESTRANT | Meitheal Pharmaceuticals Inc | 015fafb6-23f7-4566-9c23-386eee7b035d | 2024-06-17 | Warnings, Adverse reactions | Fulvestrant FULVESTRANT |
| Fulvestrant | FULVESTRANT | Avenacy, Inc. | f44cffcc-8f5e-4a4c-a36e-ab946ce86266 | 2024-02-28 | Warnings, Adverse reactions | Fulvestrant FULVESTRANT |
| Fulvestrant | FULVESTRANT | Fresenius Kabi USA, LLC | fabe9bd8-ac23-4df1-a89a-223d5cd38914 | 2024-01-31 | Warnings, Adverse reactions | Fulvestrant FULVESTRANT |
| Fulvestrant | FULVESTRANT | Sandoz Inc | 7a03f714-b109-4256-80a6-78c82127d624 | 2022-09-21 | Warnings, Adverse reactions | Fulvestrant FULVESTRANT |
| Fulvestrant | FULVESTRANT | Sandoz Inc | 141f439e-078c-4a59-acff-ebf7685f55b8 | 2022-09-13 | Warnings, Adverse reactions | Fulvestrant FULVESTRANT |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.